Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction

US6365572B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Hans Ulrich Stilz · Frankfurt am Main, DE
• Martin Gerl · Kriftel, DE
• Gary A. Flynn · Cincinnati, US
• Magda Stankova · Tucson, US
• Robert A. Binnie · Tucson, US

Key dates

• Filing date: Feb 29, 2000
• Grant date: Apr 2, 2002
• Expiry date: Feb 29, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Low molecular weight peptide derivatives which are able to act as inhibitors of the interaction between laminin and nidogen (laminin/nidogen interaction), a process for their preparation, pharmaceutical compositions prepared therefrom and their use for preparing pharmaceuticals and for identifying inhibitors of the laminin/nidogen interaction.